[TNF-alpha and soluble TNF receptor p55 in patients wtih multiple sclerosis].
In 60 patients with relapsing-remitting and secondary progressive multiple sclerosis (MS), as well as in 20 controls, tumor necrosis factor alpha (TNF-alpha) and soluble tumor necrosis factor receptor I (sTNF-RI) in the cerebrospinal fluid (CSF) and sera were detected. The results were compared with EDSS. The purpose of the study was also an evaluation if TNF-alpha and/or sTNF-RI could be markers in steroid therapy monitoring in MS patients. There was an increase of sTNF-RI in the CSF of MS patients compared with control group. The level of sTNF-RI correlated positively with TNF-alpha in the CSF of relapsing-remitting MS patients. There was no correlation between TNF-alpha as well as sTNF-RI and EDSS. There was a decrease of TNF-alpha, sTNF-RI and total lesion area in MRI after steroid therapy, but the differences did not reach statistical significance.
Geppert
A
A
Zakładu Neuroimmunologii Klinicznej Katedry Neurologii AM w Poznaniu.
Losy
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015415:Biomarkers; D001921:Brain / Q000473:pathology; D002908:Chronic Disease; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology*; D012008:Recurrence; D012720:Severity of Illness Index; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D008775:Methylprednisolone